RedHill Biopharma (RDHL) Total Liabilities (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Total Liabilities for 3 consecutive years, with $22.7 million as the latest value for Q4 2024.

  • Quarterly Total Liabilities rose 8.33% to $22.7 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $22.7 million through Dec 2024, up 8.33% year-over-year, with the annual reading at $22.7 million for FY2024, 8.33% up from the prior year.
  • Total Liabilities for Q4 2024 was $22.7 million at RedHill Biopharma, up from $21.0 million in the prior quarter.
  • The five-year high for Total Liabilities was $22.7 million in Q4 2024, with the low at $2.6 million in Q4 2022.
  • Average Total Liabilities over 3 years is $15.4 million, with a median of $21.0 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 699.77% in 2023, then grew 8.33% in 2024.
  • Over 3 years, Total Liabilities stood at $2.6 million in 2022, then skyrocketed by 699.77% to $21.0 million in 2023, then rose by 8.33% to $22.7 million in 2024.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $22.7 million, $21.0 million, and $2.6 million for Q4 2024, Q4 2023, and Q4 2022 respectively.